Does Insurance Cover Wegovy, Zepbound, or Foundayo in 2026?

Learn how insurance, Medicare, Medicaid, and 2026 self-pay programs may cover Wegovy, Zepbound, or Foundayo, including the GLP-1 Bridge.

WEIGHT MANAGEMENTACCESS, COST, & CARE

Sarina Helton, MSN, APRN, FNP-C, CAE-OM Founder, Optima Vida Healthcare

9/3/20269 min read

pink flamingo on water during daytime
pink flamingo on water during daytime

Does Insurance Cover Wegovy, Zepbound, or Foundayo in 2026?

Insurance coverage for weight-management medication expanded in 2026, but approval is still not automatic.

Wegovy, Zepbound, and Foundayo may be covered through commercial insurance, Medicare, or Medicaid. Coverage depends on the specific plan, employer benefits, prescribed indication, medication formulation, formulary, prior-authorization rules, and required pharmacy channel.

Two people with insurance cards from the same company can receive different coverage decisions. One employer may include anti-obesity medications, while another excludes them. Medicare also introduced a separate GLP-1 Bridge in July 2026, but eligibility is limited.

The most reliable coverage information comes from the member’s current formulary, plan documents, and plan-specific prior-authorization criteria.

Coverage and manufacturer prices in this article were reviewed August 31, 2026, and may change.

The Short Answer

  • Wegovy injection: Covered by some commercial plans. Eligible Medicare Part D beneficiaries may access it through the Medicare GLP-1 Bridge.

  • Wegovy tablets: Commercial coverage varies. All tablet strengths are included in the Medicare GLP-1 Bridge for eligible beneficiaries.

  • Wegovy HD: Commercial coverage varies. The current CMS product list includes Wegovy HD in the Bridge for eligible beneficiaries.

  • Zepbound: Covered by some commercial plans. The Bridge includes only the Zepbound KwikPen—not the single-dose pens or vials.

  • Foundayo tablets: Commercial formulary adoption varies. All Foundayo strengths are included in the Bridge for eligible beneficiaries.

Coverage is not guaranteed because a medication is FDA-approved or medically appropriate.

Why Does Coverage Vary?

Commercial plans are often administered by large insurance companies, but employers and other plan sponsors select many of the benefits.

A plan may:

  • Cover all or selected FDA-approved anti-obesity medications

  • Prefer one product or formulation

  • Require prior authorization or step therapy

  • Exclude obesity medication entirely

  • Require participation in a designated weight-management program

  • Require use of a specific pharmacy, telehealth company, or clinical vendor

The insurance-company name alone does not predict coverage. Aetna, BCBS, Cigna, or UnitedHealthcare members can have different benefits depending on the employer and plan contract.

What Is a Formulary?

A formulary is a plan’s list of covered medications. Products may be classified as preferred, nonpreferred, specialty, nonformulary, or excluded.

The formulary may also identify:

  • Prior-authorization requirements

  • Step therapy

  • Quantity limits

  • Approved pharmacies or mail-order requirements

  • Copay or coinsurance tiers

  • Renewal criteria

  • Formulation restrictions

A medication’s appearance on a formulary does not mean it will be approved for every member or indication.

What Is Prior Authorization?

Prior authorization is the insurer’s review process before it agrees to pay for a medication. The requested information may include:

  • Height, weight, and BMI

  • Weight-related medical conditions

  • Previous weight-management treatment

  • Current nutrition and physical-activity program

  • Previous medication trials

  • Contraindications to preferred medications

  • Documentation of FDA-labeled eligibility

  • Confirmation that another GLP-1 medication is not being used concurrently

  • Participation in a structured program

The insurer or benefit administrator makes the coverage decision. A prior authorization is separate from the prescriber’s clinical decision and the pharmacy’s dispensing process.

Learn More: Prior Authorization for Weight-Loss Medication: What Patients Should Expect (Publish 09-17-2026)

Common Coverage Criteria

Many plans begin with the FDA-labeled adult eligibility for chronic weight management:

  • BMI of at least 30 kg/m², or

  • BMI of at least 27 kg/m² with at least one weight-related condition

Weight-related conditions can include hypertension, dyslipidemia, type 2 diabetes or prediabetes, obstructive sleep apnea, and cardiovascular disease.

Insurance plans may impose narrower rules, including a higher BMI, a specified comorbidity, a six-month program requirement, or step therapy. Meeting clinical prescribing criteria does not override a contractual plan exclusion.

Learn More: Who Qualifies for Prescription Weight-Loss Medication? (Publish 09-16-2026)

Wegovy Coverage in 2026

Wegovy is available as weekly injections, including Wegovy HD, and as daily tablets. A plan may cover one formulation, prefer one over another, require step therapy, or exclude all forms for weight management.

Cardiovascular-Risk Reduction

Wegovy has an FDA-approved indication to reduce major cardiovascular events in certain adults with established cardiovascular disease and overweight or obesity.

Some Medicare and commercial plans may evaluate Wegovy under this indication even when routine obesity-drug coverage is restricted. Cardiovascular risk factors alone do not necessarily establish the documented cardiovascular disease required by a specific policy.

MASH

Standard Wegovy injection also has an FDA-approved indication for certain adults with noncirrhotic metabolic dysfunction-associated steatohepatitis and moderate-to-advanced fibrosis.

Coverage under this indication may require specialist involvement, fibrosis documentation, and use of a specified formulation. A general fatty-liver diagnosis does not establish eligibility.

Zepbound Coverage in 2026

Zepbound is covered by some commercial plans for chronic weight management. Requirements can include qualifying BMI, weight-related conditions, lifestyle-program documentation, prior authorization, and use of a preferred formulation or pharmacy.

Obstructive Sleep Apnea

Zepbound is also FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity.

Insurance review under the sleep-apnea indication may consider sleep-study results, apnea-hypopnea index, obesity documentation, and other plan-specific records. Coverage for this indication is distinct from coverage solely for weight management.

Foundayo Coverage in 2026

Foundayo is orforglipron, a once-daily oral GLP-1 receptor agonist approved for chronic weight management in eligible adults.

Because it is newer than Wegovy and Zepbound, commercial formulary adoption is still developing. A plan may list it as preferred, nonpreferred, subject to prior authorization or step therapy, or excluded with other obesity medications.

FDA approval does not automatically place a new medication on every formulary.

Medicare GLP-1 Bridge

CMS launched the temporary Medicare GLP-1 Bridge on July 1, 2026. It is scheduled to operate through December 31, 2027.

The current Bridge includes:

  • Foundayo tablets

  • Wegovy injections, including Wegovy HD

  • Wegovy tablets

  • Zepbound KwikPen

Zepbound single-dose pens and vials are not included.

Eligible beneficiaries pay a $50 copay for a monthly supply. The program operates outside the Part D payment flow, so the Part D deductible does not apply, the $50 does not count toward true out-of-pocket costs, and the low-income subsidy does not reduce the copay. Coupons and discount programs cannot be applied to Bridge claims.

Learn More: Medicare Coverage for Wegovy, Zepbound, and Foundayo in 2026

Medicare Bridge Clinical Criteria

The Bridge is available to eligible adults with Medicare Part D coverage when a covered medication is prescribed for weight management and CMS requirements are met.

At the time GLP-1 therapy was initiated, the beneficiary must have met one of the following pathways:

BMI of at Least 35

No additional listed comorbidity is required under this pathway.

BMI of at Least 30 With a Listed Condition

  • Heart failure with preserved ejection fraction

  • Uncontrolled hypertension, as defined by CMS

  • Chronic kidney disease stage 3a or higher

BMI of at Least 27 With a Listed Condition

  • Prediabetes as defined by American Diabetes Association criteria

  • Previous myocardial infarction

  • Previous stroke

  • Symptomatic peripheral artery disease

The Bridge also requires current and ongoing lifestyle modification involving structured nutrition and physical activity consistent with the applicable FDA label. Prior authorization is processed through the CMS Bridge rather than the beneficiary’s Part D plan.

Who Is Not Eligible for the Bridge?

The Bridge is for weight-management use. A beneficiary is not eligible when the GLP-1 is prescribed for an indication coverable under the regular Part D benefit.

CMS specifically identifies type 2 diabetes, moderate-to-severe obstructive sleep apnea, and noncirrhotic MASH with moderate-to-advanced fibrosis. A beneficiary with one of these diagnoses is ineligible for the Bridge even if the current Part D plan does not cover the requested GLP-1 for that condition.

CMS also reviews whether the beneficiary previously received a GLP-1 through Part D during 2026. Part D enrollment, the prescribed indication, the clinical criteria at therapy initiation, and prior coverage history all affect eligibility.

The Bridge is not universal Medicare coverage for everyone seeking weight loss.

What About Medicaid?

Medicaid coverage varies by state. A state program may cover selected anti-obesity medications, use a preferred-drug list, require prior authorization, limit coverage to certain diagnoses, require a designated program, or exclude weight-management drugs.

Managed-care plans must follow applicable state requirements, although their administrative procedures and preferred products may differ.

Commercial manufacturer copay cards generally exclude people enrolled in Medicaid, Medicare, TRICARE, VA healthcare, or other government-funded programs.

What About TRICARE and VA Coverage?

TRICARE and Veterans Affairs use separate federal formularies and clinical requirements. Coverage may depend on the diagnosis, BMI, comorbidities, previous treatment, preferred medication, and authorized care setting.

Government-insured beneficiaries are generally excluded from commercial manufacturer copay-card programs.

Benefit Exclusion vs. Prior-Authorization Denial

A benefit exclusion is different from a prior-authorization denial.

  • A prior-authorization denial means the request did not satisfy the criteria or documentation reviewed. The denial may sometimes be corrected or appealed.

  • A benefit exclusion means the plan contract does not include the medication category or service.

An appeal usually cannot create a benefit that the employer did not purchase. However, a medication may be evaluated under another FDA-approved indication when that diagnosis is accurate, supported by the medical record, and covered by the plan.

Examples include Wegovy for qualifying cardiovascular-risk reduction, Wegovy for qualifying MASH, and Zepbound for qualifying obstructive sleep apnea.

Common Reasons for Denial

Coverage may be denied because:

  • Anti-obesity medications are excluded

  • The product is not on the formulary

  • BMI or comorbidity criteria were not met or documented

  • Step therapy was not completed

  • Program participation was not documented

  • Another GLP-1 is already being used

  • The requested formulation or pharmacy is not preferred

  • Records were incomplete

  • The authorization expired

  • Renewal criteria were not met

  • Billing or diagnosis information was incorrect

The denial notice identifies the reason and available appeal rights.

What Is Step Therapy?

Step therapy requires trial of one or more preferred treatments before the plan will cover the requested medication. The sequence varies by plan.

Contraindications, allergies, interactions, previous adverse effects, and documented treatment failures may be relevant to a step-therapy exception. Approval is not guaranteed.

Continued Coverage

Initial approval does not guarantee indefinite payment. Plans may require reauthorization every six or twelve months.

Renewal criteria can include documented weight reduction or maintenance, ongoing program participation, medication adherence, continued eligibility, and updated clinical records. Coverage can also change when an employer changes benefits, a new plan year begins, a formulary changes, or another medication becomes preferred.

Wegovy Self-Pay Prices

Novo Nordisk’s current self-pay pricing varies by formulation and dose.

Wegovy Injections

  • New patients meeting the offer terms: $199 per month for the first two fills of the 0.25 mg or 0.5 mg pens through December 31, 2026

  • Standard Wegovy injection strengths from 0.25 mg through 2.4 mg: $349 per month

  • Wegovy HD 7.2 mg: $399 per month

Wegovy Tablets

  • 1.5 mg: $149 per month

  • 4 mg: $199 per month as of August 31, 2026

  • 9 mg and 25 mg: $299 per month

The manufacturer defines a month as one box of four injection pens or one bottle of 30 tablets. Eligibility and restrictions apply, and Novo Nordisk may change or end the program.

Zepbound Self-Pay Prices

Lilly’s current regular direct-to-patient prices for a one-month supply of Zepbound KwikPen are:

  • 2.5 mg: $299

  • 5 mg: $399

  • 7.5 mg: $499

  • 10 mg: $699

  • 12.5 mg: $699

  • 15 mg: $699

Eligible participants may receive a $449 purchase offer for the 7.5 mg, 10 mg, 12.5 mg, and 15 mg KwikPen doses. Continued eligibility generally requires the refill purchase within 45 days of the previous delivery or receipt date.

These prices do not apply to Zepbound single-dose pens. Taxes, fees, eligibility requirements, and restrictions may apply. Lilly may modify or end the program.

Foundayo Self-Pay Prices

Lilly’s current regular prices for a 30-day supply are:

  • 0.8 mg: $149

  • 2.5 mg: $199

  • 5.5 mg: $299

  • 9 mg: $299

  • 14.5 mg: $349

  • 17.2 mg: $349

An eligible purchase offer reduces the 14.5 mg and 17.2 mg strengths to $299. Continued eligibility generally requires purchase of the refill within 45 days of the previous delivery or receipt date.

Taxes, fees, eligibility requirements, and restrictions may apply. Lilly may modify or end the program.

Commercial Savings Cards

Commercially insured patients may qualify for manufacturer savings programs when eligibility requirements are met. A savings card does not create insurance coverage.

Limitations can include maximum monthly or annual savings, expiration dates, approved formulations, designated pharmacies, and exclusion of government-insured patients.

When medication is purchased outside insurance, the payment may not count toward the deductible or annual out-of-pocket maximum. Employer accumulator or maximizer programs can also affect how manufacturer assistance is credited.

OVH Clinical-Care Fees

Optima Vida Healthcare’s clinical-care fees are separate from medication costs:

  • Initial evaluation: $99

  • Ongoing care: $25 per month

Ongoing care includes clinical check-ins, refill evaluations, treatment monitoring, and patient messaging. Medication, laboratory testing, and separately scheduled video visits are not included.

Questions for the Insurance Plan

Useful questions include:

  • Is FDA-approved anti-obesity medication a covered benefit or an exclusion?

  • Is the exact medication and formulation covered?

  • Which medication is preferred?

  • Is prior authorization or step therapy required?

  • What clinical documentation is required?

  • Is a designated program or pharmacy required?

  • What is the estimated copay or coinsurance?

  • What are the renewal criteria?

  • Are different criteria used for cardiovascular disease, MASH, or obstructive sleep apnea?

  • What is the call-reference number?

Appealing a Denial

An effective appeal addresses the specific reason stated in the denial notice. Relevant information may include corrected height, weight, BMI, diagnoses, previous medication trials, contraindications to preferred alternatives, program documentation, and missing clinical records.

Appeal rights and external-review options vary by plan. A medical-necessity appeal may not overcome a contractual benefit exclusion.

How OVH Helps

When clinically appropriate, Optima Vida Healthcare (OVH) may document baseline and current BMI, relevant diagnoses, previous treatment, clinical eligibility, and treatment response; submit prior authorization; respond to requests for information; and support a medically reasonable appeal.

OVH cannot guarantee coverage, change an employer exclusion, control processing time, or guarantee appeal approval. Submitted information must be truthful and supported by the medical record.

The Bottom Line

Wegovy, Zepbound, and Foundayo may be covered in 2026, but coverage remains plan-specific.

Commercial coverage depends heavily on employer benefit design, formulary status, prior authorization, preferred formulation, and pharmacy channel. Medicaid, TRICARE, and VA coverage follow different rules.

Medicare access expanded through the temporary GLP-1 Bridge. Eligible Part D beneficiaries can receive covered Foundayo, Wegovy, or Zepbound KwikPen products for a $50 monthly copay, but clinical and program criteria apply.

When insurance does not cover treatment, manufacturer self-pay programs may reduce the cash price. These programs are not insurance and can change.

Learn More About Medical Weight Management

Start an OVH Weight-Management Evaluation →

Visit ovhmed.com for more information →

Prescription medication is not guaranteed. Prescribing decisions are made by a licensed healthcare professional after an appropriate clinical evaluation.

Sarina Helton, MSN, APRN, FNP-C, CAE-OM
Founder, Optima Vida Healthcare

Educational Disclaimer

This article is provided for general educational purposes only. It does not provide individualized medical, insurance, legal, or financial advice or guarantee coverage, medication availability, or a specific price. Formularies, Medicare and Medicaid rules, manufacturer programs, eligibility criteria, and prices may change.

Information reviewed August 31, 2026.

Sources

GLP-1 insurance coverage 2026